Active symptom control with or without oral vinorelbine in patients with relapsed malignant pleural mesothelioma (VIM): A randomised, phase 2 trial

EClinicalMedicine 2022 May 19 [Link] Dean A Fennell, Catharine Porter, Jason Lester, Sarah Danson, Paul Taylor, Michael Sheaff, Robin M Rudd, Aarti Gaba, Sara Busacca, Lisette Nixon, Georgina Gardner, Liz Darlison, Charlotte Poile, Cathy Richards, Peter-Wells Jordan, Gareth Griffiths, Angela Casbard Abstract Background: Currently, there is no US Food and Drug Administration approved therapy for…

Read More

High RRM1 Expression Is Associated with Adverse Outcome in Patients with Cisplatin/Vinorelbine-treated Malignant Pleural Mesothelioma

Anticancer Research 2015 December [Link] Zimling ZG, Santoni-Rugiu E, Bech C, Sørensen JB. Abstract Background/Aim A possible predictive impact of ribonucleotide-reductase subunit-1 (RRM1) on vinorelbine efficacy in non-small cell lung cancer (NSCLC) has been previously reported. The present study aimed to further explore this finding in malignant pleural mesothelioma (MPM). Materials and Methods Seventy-one patients…

Read More

Systemic Treatments for Mesothelioma: Standard and Novel

Current Treatment Options in Oncology. 2008 Jun;9(2-3):171-9. Epub 2008 Sep 3. [Link] Kindler HL. Section of Hematology/Oncology, University of Chicago, Chicago, IL 60637, USA. hkindler@medicine.bsd.uchicago.edu Abstract Systemic therapy is the only treatment option for the majority of mesothelioma patients, for whom age, co-morbid medical illnesses, non-epithelial histology, and locally advanced disease often preclude surgery. For…

Read More

Cisplatin and vinorelbine first-line chemotherapy in non-resectable malignant pleural mesothelioma

British Journal of Cancer. 2008 Jun 10. [Epub ahead of print] [Link] Sørensen JB, Frank H, Palshof T. 1Department Oncology, Finsen Centre/National University Hospital, 9 Blegdamsvej, Copenhagen DK-2100, Denmark. Abstract The aim was to evaluate the activity of cisplatin and vinorelbine in previously untreated, inoperable patients having histologically verified malignant pleural mesothelioma (MPM), normal organ…

Read More

Response of a Patient with Pleural and Peritoneal Mesothelioma after Second-Line Chemotherapy with Lipoplatin and Gemcitabine

Oncology. 2007;73:426-429. [Link] Karpathiou G, Argiana E, Koutsopoulos A, Froudarakis ME. Department of Pneumonology, Medical School Democritus University of Thrace, Alexandroupolis, Greece. Abstract We report the case of a 56-year-old patient with malignant pleural mesothelioma of epithelial type, who responded to second-line chemotherapy with lipoplatin plus gemcitabine. Diagnosis and staging of the disease was done…

Read More

Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial

Lancet. 2008 May 17;371(9625):1685-1694. [Link] Muers MF, Stephens RJ, Fisher P, Darlison L, Higgs CM, Lowry E, Nicholson AG, O’Brien M, Peake M, Rudd R, Snee M, Steele J, Girling DJ, Nankivell M, Pugh C, Parmar MK; on behalf of the MS01 Trial Management Group. Leeds General Infirmary, Leeds, UK. Abstract Background: Malignant pleural mesothelioma…

Read More

Cost-effectiveness of pemetrexed plus cisplatin: malignant pleural mesothelioma treatment in UK clinical practice

Value in Health. 2008 Jan-Feb;11(1):4-12. [Link] Cordony A, Le Reun C, Smala A, Symanowski JT, Watkins J. M-TAG Pty Ltd, A Unit of IMS Health, St Leonards, NSW, Australia. acordony@au.imshealth.com Abstract Objectives: Findings from the largest randomized phase III trial in patients with unresectable malignant pleural mesothelioma (EMPHACIS study; n = 448) were used to…

Read More